Drug Profile
Niclosamide - UNION Therapeutics
Alternative Names: ATx 201 - UNION Therapeutics; ATx201 OINTMENT - UNION Therapeutics; UNI-911; UNI91103; UNI91104Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator AntibioTx
- Developer UNION Therapeutics
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Atopic dermatitis; Impetigo
- Phase I/II Eczema
Most Recent Events
- 11 Oct 2023 Adverse events data from a phase II/III PROTECT-V trial in COVID-2019-infections presented at the IDWeek 2023 (IDW-2023)
- 30 Mar 2022 Phase-II/III clinical trials in COVID-2019 infections (Prevention) in India (Intranasal)
- 23 Feb 2022 Discontinued - Phase-II for COVID-2019 infections in Germany (Intranasal) (NCT04932915) (EudraCT2021-001036-25)